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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disorder characterised by progressive
degeneration of motor neurons leading to death, typically within 3–5 years of symptom onset. The diagnosis of ALS is
largely reliant on clinical assessment and electrophysiological findings. Neither specific investigative tools nor reliable
biomarkers are currently available to enable an early diagnosis or monitoring of disease progression, hindering the design of
treatment trials.
Methodology/Principal Findings: In this study, using the well-established SOD1G93A mouse model of ALS and a new in-
house ELISA method, we have validated that plasma neurofilament heavy chain protein (NfH) levels correlate with both
functional markers of late stage disease progression and treatment response. We detected a significant increase in plasma
levels of phosphorylated NfH during disease progression in SOD1G93A mice from 105 days onwards. Moreover, increased
plasma NfH levels correlated with the decline in muscle force, motor unit survival and, more significantly, with the loss of
spinal motor neurons in SOD1 mice during this critical period of decline. Importantly, mice treated with the disease
modifying compound arimoclomol had lower plasma NfH levels, suggesting plasma NfH levels could be validated as an
outcome measure for treatment trials.
Conclusions/Significance: These results show that plasma NfH levels closely reflect later stages of disease progression and
therapeutic response in the SOD1G93A mouse model of ALS and may potentially be a valuable biomarker of later disease
progression in ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disorder characterised by progressive degeneration of motor
neurons in the motor cortex, brain stem and spinal cord, leading
to paralysis and death, typically within 3–5 years from symptom
onset. Riluzole is the only FDA-approved treatment for ALS,
which prolongs median survival by only 2–3 months in patients
treated for at least 18 months [1]. Importantly, the greatest benefit
of Riluzole is observed when treatment is initiated early in the
course of the disease, highlighting the importance of early
intervention in ALS [2]. In the absence of a reliable diagnostic
biomarker, the recognition of ALS relies largely on clinical
assessment and electrophysiological findings, which provide
evidence of upper and lower motor neuron involvement [3].
The lack of more specific investigative tools and of easily
measurable biomarkers typically results in a 12–14 month delay
between symptom onset to diagnosis, for both sporadic (sALS) and
familial ALS (fALS) [4]. This delay not only prevents patients from
receiving early administration of the only available therapy,
Riluzole, but also impedes their early recruitment to clinical trials,
thereby reducing the likelihood of success of potential disease-
modifying agents. Therefore, there is an urgent need to develop
biomarkers for ALS, to both speed up diagnosis and to monitor
disease progression. This is particularly true for clinical trials,
where such a biomarker would be invaluable for statistical power
and as an indicator of both positive and negative responses to
treatment.
Although the precise underlying pathology of ALS is not yet
fully understood, a number of molecular mechanisms have been
identified that are present in both human ALS and in mouse
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models of ALS. Transgenic mice carrying the mutant human Cu/
Zn superoxide dismutase 1(SOD1) gene, causative for approximately
10–20% of familial ALS cases [5], have a disease phenotype that
resembles that of ALS patients including progressive motor neuron
degeneration accompanied by gradual muscle paralysis and
premature death [6]. These mice have been invaluable in
identifying several pathological mechanisms that contribute to
ALS. ALS is now known to be a multifactorial disorder that
involves excitotoxicity, dysfunctional RNA metabolism, mitochon-
drial dysfunction, endoplasmic reticulum stress, proteasomal
dysfunction, activation of inflammatory pathways and, important-
ly for this study, impaired axonal transport and protein
aggregation [7]. Several proteins have been shown to aggregate
in tissue of ALS patients and animal models of ALS including
structural proteins of the axonal cytoskeleton such as neurofila-
ments [8]. Despite the complexity of ALS pathogenesis, the
multitude of molecular mechanisms involved in the disease process
not only provide targets for development of novel therapeutics but
may also provide clues for the development of biomarkers of
disease progression.
The neurofilament proteins (Nfs) are a major component of the
cytoskeleton and play an important role in the maintenance of
axonal calibre [9]. Nfs are assembled into a unique heteropolymer
structure with a specific stoichiometric composition of at least four
subunits: neurofilament light chain (NfL, 68 kDa), neurofilament
medium chain (NfM, 150 kDa), neurofilament heavy chain (NfH,
200 kDa) and alpha-internexin (INA, 66 kDa) [10]. The three
neurofilament subunits differ mainly in the length of the C-
terminal tail domain, which results in different states of
phosphorylation and susceptibility to proteases [11]. Mutations
in Nfs have been reported in several neurodegenerative diseases,
including Alzheimer’s disease (AD), Parkinson’s disease (PD),
Charcot-Marie-Tooth Disease, giant axonal neuropathy, diabetic
neuropathy, progressive supranuclear palsy, spinal muscular
atrophy, as well as ALS [9]. Although only a small number of
variants in the NfH gene have been identified in approximately
1% sALS patients [12,13], one common pathological finding of
both sALS and fALS is the accumulation of phosphorylated Nfs in
the perikaryon and in axonal spheroids, which are normally only
present in distal axons and nerve terminals [14]. Manipulations of
the stoichiometry of the three Nf subunits has been shown to
facilitate the development of early-onset motor neuron death in
transgenic mouse models of ALS [15,16,17], thus supporting the
critical involvement of Nfs in ALS pathology.
Monitoring of tissue specific components released into biological
fluids during disease progression can be used to aid diagnosis and
reflect pathological severity [4,18,19]. Nfs levels in the cerebro-
spinal fluid (CSF), being the closest body fluid compartment to the
CNS, have been investigated as potential disease biomarkers in
several neurological disorders. Recent studies have shown that
CSF Nf levels might serve as a prognostic marker in multiple
sclerosis [20], may assist in the differential diagnosis between
frontotemporal dementia (FTD) and early onset AD [21], and may
help distinguish Parkinsonian syndromes in combination with CSF
tau levels [22,23]. Furthermore, CSF Nf levels are much higher in
ALS than in other neurodegenerative disorders such as AD [23–
26] and correlate inversely with disease duration [27]. It has also
been suggested that the phosphorylation state of Nfs can be
indicative of neuronal pathology and high levels of phosphorylated
NfH have been detected in neurodegenerative disorders [9].
However, because of its invasive nature, serial CSF sampling is not
tolerated by all patients and CSF is clearly not the ideal biofluid for
repeated sampling for the purpose of monitoring progression in
ALS. Thus, a functionally validated Nf-based blood biomarker for
the longitudinal monitoring of disease development and informa-
tive of treatment response would be highly desirable.
Previous studies have identified a crucial analytical problem in
accurate, reproducible quantification of NfH levels in blood
samples due to the presence of Nf aggregates [28]. These
aggregates are a source of endogenous binding for NfH in plasma
that leads to a ‘hook effect’ during serial dilutions. To overcome
this problem, we recently developed a method in which Nf
aggregates are gently disaggregated, allowing accurate and highly
sensitive quantification of plasma NfH levels using ELISA [28]. In
this study, we have used this method to determine the longitudinal
changes in plasma NfH levels in transgenic mice carrying mutant
human SOD1G93A gene during disease progression. Importantly,
we have correlated these changes with the decline in neuromus-
cular function and motor neuron survival. In addition, we
undertook a differential analysis of the NfH phosphorylation
status. Thus, in separate assays, we examined hyperphosphory-
lated and variably-phosphorylated NfH levels. Finally, in order to
establish the potential of this approach as an outcome measure in
clinical trials, we examined whether plasma NfH levels are
improved following treatment with arimoclomol, which we have
previously shown to modify disease progression in SOD1G93A mice
[29,30], and which is currently in a PhaseII/III clinical trial in
mutant SOD1 related fALS patients [31].
Results
Plasma NfH Levels in SOD1 Mice Increase Significantly
from a Late Symptomatic Stage
Hyperphosphorylated (NfHSMI34) and variably-phosphorylated
(NfHSMI35) NfH levels in plasma from mice in each experimental
group were determined at various stages of disease using a 4-layer
sandwich ELISA.
As can be seen in Fig. 1A, in WT mice, the mean plasma levels
of hyperphosphorylated NfHSMI34 remained unchanged during
the duration of the study, up to 120 days of age (Friedman test,
p = 0.518). In contrast, in SOD1 mice, there was a significant
change in NfHSMI34 levels during overall disease progression
(Friedman test, p,0.0001). Plasma NfHSMI34 levels were higher in
SOD1 mice than in WT littermates at all ages examined, although
this difference only reached statistical significance from 105 days
of age onwards (65 days: SOD1 46.2613.1, WT 40.668.9;
90 days: SOD1 81.8615.8, WT 52.7612.2; 105 days: SOD1
155.4619.3, WT 26.766.8, p,0.0001; 120 days: SOD1
328.4640.3, WT 43.5617.3, p,0.0001; mean 6 S.E.M ng/
mL; Mann-Whitney test; Fig. 1A).
The mean levels of plasma NfHSMI35 (Fig. 1B), the variably-
phosphorylated NfH which is considered to be the less patholog-
ical form of NfH, also remained stable in WT mice throughout the
study period (Friedman test, p = 0.405). In contrast, in SOD1
mice, plasma NfHSMI35 levels increased significantly throughout
disease progression (Friedman test, p,0.0001), although not as
dramatically as NfHSMI34, the more pathological phosphoform,
and became significantly higher than WT from 105 days of age
onwards (65 days: SOD1 74.0620.8, WT 58.0616.0; 90 days:
SOD1 68.8614.8, WT 46.2614.2; 105 days, SOD1 104.8617.0,
WT 34.7611.6, p = 0.002; 120 days, SOD1 161.0621.5, WT
21.669.9, p,0.0001; mean 6 S.E.M ng/mL; Mann-Whitney
test; Fig. 1B).
In addition, in WT mice, a comparison of NfHSMI35 and
NfHSMI34 levels showed that plasma levels of NfH were not only
low, but that there was also no difference in the relative levels of
the two NfH phosphoforms at any age examined (Mann-Whitney
test, p = 0.479, 0.353, 0.817, 0.565 at 65, 90, 105, and 120 days,
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respectively; data not shown). In contrast, in SOD1 mice, a
comparison of the relative levels of the two NfH phosphoforms
revealed that levels of NfHSMI34 compared with NfHSMI35
increased as disease advanced (comparison NfHSMI34: NfHSMI35
at 65 days: p = 0.507; 90 days: p= 0.546; 105 days: p = 0.068;
120 days: p= 0.004; Mann-Whitney Test). Thus, in SOD1 mice
plasma levels of the more pathological NfHSMI34 phosphoform
increased to a greater extent than the less pathological NfHSMI35.
Correlations between Plasma NfH Levels and Functional
Measures of Disease Progression in SOD1 Mice
Increased plasma NfH levels inversely correlate with grip
strength in SOD1 mice. In order to establish the relationship
between the changes in plasma NfH levels detected in SOD1 mice
and the decline in neuromuscular function that occurs as disease
progresses in these mice, a number of functional outcome
measures were investigated. Firstly, at each time point, grip
strength and body weight was determined in each mouse prior to
blood collection. The analysis of the correlation between plasma
NfH levels and the corresponding mean grip strength is
summarised in Fig. 2. The results show that in SOD1 mice, there
was a moderate-to-strong inverse correlation between plasma NfH
levels and grip strength at all time points examined, 65, 90, 105
and 120 days (Spearman’s rho (R) : NfHSMI34 v.s. GS: 20.583,
p,0.0001; NfHSMI35 v.s. GS: 20.335, p,0.0001; Fig. 2A & 2B).
No such correlation in plasma NfH levels and grip strength was
observed in WT mice at any age examined (data not shown).
Increased plasma NfH levels correlate with the decline in
isometric muscle force in hindlimb muscles of SOD1
mice. In order to obtain a more detailed assessment of the
relationship between plasma NfH levels and quantitative func-
tional markers of disease progression, an in vivo physiological
assessment of isometric muscle force in the hindlimb muscles of
SOD1 mice was undertaken. This physiological assessment of
isometric muscle force of specific muscles provides a more sensitive
and quantitative assessment of functional decline than grip
strength analysis, which can only detect general motor deficits in
SOD1 mice relatively late in the disease process, when many
motor neurons have already died. We have previously generated
similar physiological data in our lab in SOD1 mice at various
stages of disease ranging from early symptomatic (90 days) to end-
stage disease (130 days) [29,30,32]. We then examined whether
plasma NfH levels correlate with this profile of functional decline
in SOD1 mice.
Figure 1. Longitudinal assessment of plasma NfH levels in WT
and SOD1 mice. The graphs show the mean plasma level (ng/ml) of
A) NfHSMI34 and B) NfHSMI35 in SOD1 (circles; n = 19) and WT (squares;
n = 13) mice at 65 (pre-symptomatic), 90 (early symptomatic), 105 (late
symptomatic), and 120 (end stage) days of age. Error bars = S.E.M.
Friedman test was used for analysis of the pattern of plasma NfH levels
during disease progression, and Mann-Whitney Test was then used for
group comparison at each time point. **p = 0.002, ***p,0.0001.
doi:10.1371/journal.pone.0040998.g001
Figure 2. The correlation between grip strength and plasma
NfH levels in SOD1 mice during disease progression. The graphs
show the relationship between mean grip strength (g) and plasma NfH
phosphoform levels (ng/mL) in individual SOD1 mice (n = 16) at 65, 90,
105, and 120 days of age. A) There is a strong inverse correlation
between plasma NfHSMI34 levels and grip strength in SOD1 mice
(Spearman’s rho=20.583, p,0.0001). The best-fit line (dashed line) is
shown. B) There is a moderate inverse correlation between plasma
NfHSMI35 and grip strength in SOD1 mice (Spearman’s rho =20.335,
p,0.0001). The best-fit line (dashed line) is shown.
doi:10.1371/journal.pone.0040998.g002
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Typical examples of tetanic and twitch force traces from the TA
muscles of 105-day-old WT and SOD1 mice are shown in Fig. 3A.
The mean maximum twitch and tetanic force of the Tibialis
Anterior (TA) and Extensor Digitorum Longus (EDL) muscles of
WT and SOD1 at various stages of disease is summarised in
Fig. 3B and 3C, respectively, which shows the well established,
progressive decrease in muscle force in both TA and EDL muscles
that occurs in SOD1 mice as they age. The results also show that
in SOD1 mice, TA muscles were affected earlier in disease and to
a greater extent than EDL muscles. Thus, the maximum tetanic
force (Fig. 3C; mean6S.E.M.) in SOD1 TA was 56.765 g (n= 13)
at 90 days, 21.163 g (n= 16) at 105 days and 19.563.5 g (n = 12)
at 120 days. When expressed as a percentage of WT TA muscle
force in age-matched WT mice, the force produced by SOD1 TA
was 41.7% at 90 days, 15.3% at 105 days and 12% at 120 days
(p,0.0001 at each time point; Mann-Whitney test). The decline in
force in SOD1 EDL muscles occurred at a steadier, slower pace.
Thus, in SOD1 EDL muscles the force produced was 24.761.5 g
(n = 15) at 90 days, 15.761.6 g (n = 19) at 105 days and
13.761.0 g (n = 11) at 120 days, which was 68.6%, 43.9% and
33.3% of the force produced in WT EDL muscles at the respective
ages (p,0.01; ,0.0001; ,0.0001, respectively; Mann-Whitney
test). A similar pattern of decline was also found in the twitch
tension of TA and EDL muscles of SOD1 mice (Fig. 3B).
As shown in Fig. 3D, an exponential regression analysis of the
decline in maximum TA muscle force at 90, 105 and 120 days of
age (indicated by the respective arrows) and their corresponding
plasma NfHSMI34 (black squares) or NfHSMI35 (black triangles)
levels in SOD1 mice was undertaken. It can be seen that there is a
moderate-strong correlation between muscle force and plasma
NfH levels in SOD1 mice (R2= 0.79 and 0.82 for NfHSMI34 and
NfHSMI35 respectively).
Increased plasma NfH levels correlate with motor unit
loss in SOD1 mice. Examples of typical motor unit traces from
the EDL muscle of 105-day-old SOD1 and WT mice are shown in
Fig. 4A. The number of functional motor units that survived in
EDL muscles was also determined in SOD1 mice at 90, 105 and
120 days of age and the results are summarised in Fig. 4B. In WT
mice, the number of motor units innervating EDL muscles
remained constant over the course of the study and the number of
motor units innervating EDL (mean6S.E.M.) was found to be
26.660.4 (n = 14) at 90 days, 30.860.4 (n = 10) at 105 days and
25.760.5 (n = 6) at 120 days. In contrast, in SOD1 mice, a
significant number of motor units had already died by 90 days,
with 22.761.2 (n = 17) motor units innervating EDL, a 15%
decline compared with WT (p,0.05). Between 90–105 days, there
was a 60% decrease in the number of motor units innervating
EDL muscles of SOD1 mice and only 12.660.5 (n = 15) motor
units innervated EDL (p,0.01). This decline in motor unit
survival in SOD1 mice plateaued at this level, so that by 120 days,
10.761.0 (n = 11; p,0.01) motor units innervated EDL.
Fig. 4C shows the results of an exponential regression analysis of
the decline in motor unit survival in EDL muscles at 90, 105 and
120 days (indicated by the respective arrows) and the correspond-
ing plasma NfHSMI34 (black squares) or NfHSMI35 (black triangles)
levels in SOD1 mice. Motor unit loss, expressed as a percentage of
motor unit survival in age matched WT mice, can be fitted into an
exponential regression with R2= 0.70 for NfHSMI34 and R2= 0.73
for NfHSMI35, indicating a modest correlation between the extent
of EDL motor unit loss and plasma NfH levels in SOD1 mice.
Increased plasma NfH levels directly correlate with the
extent of motor neuron death in the spinal cord of SOD1
mice. The defining disease characteristic in both ALS patients
and in mouse models is motor neuron degeneration. Therefore, in
order to determine if changes in plasma NfH levels in SOD1 mice
were a good reflection of the extent of motor neuron degeneration,
we next established the extent of motor neuron survival in the
lumbar spinal cord of WT and SOD1 mice at various stages of
disease. Examples of Nissl stained spinal cord sections, showing the
lumbar ventral horn of 105 day old WT and SOD1 mice are
shown in Fig. 5A. The results are summarised in Fig. 5B which
shows the mean motor neuron survival in 90, 105 and 120 day old
SOD1 mice expressed as a percentage of WT. It can be seen that
by 90 days, a significant number of motor neurons have already
died in SOD1 mice and only 60.861.4% of motor neurons survive
compared with WT littermates (p,0.01). Motor neurons continue
to die in SOD1 mice as disease progresses, so that by 105 days,
44.861.2% of motor neurons survive (p,0.01) and by 120 days
this is further reduced and only 29.061.3% of motor neurons
survive (p,0.01; Mann-Whitney test).
In order to establish whether the changes detected in plasma
NfH levels correlate with the extent of motor neuron degeneration
in SOD1 mice, an exponential regression analysis of motor neuron
survival and plasma NfH levels was undertaken. Figure 5C
summarises the results and shows the decline in motor neuron
survival in SOD1 mice at 90, 105 and 120 days of age (indicated
by the respective arrows) and corresponding plasma NfHSMI34
(black squares) or NfHSMI35 (black triangles) levels. It can be seen
that the decline in motor neuron survival observed in SOD1 mice
during disease progression fits into an exponential regression with
R2= 0.99 for both NfHSMI34 and NfHSMI35 (p-value of coefficient:
0.03 and 0.006, respectively). This analysis shows that there is a
very strong correlation between the extent of motor neuron death
and plasma levels of both NfHSMI34 and NfHSMI35 in SOD1 mice.
Plasma NfH Levels Reflect the Disease-modifying Effects
of Arimoclomol in SOD1 Mice
Since plasma NfH levels appear to be a good reflection of the
decline in neuromuscular function in SOD1 mice, we next
examined whether plasma NfH levels could reflect the improve-
ments observed in SOD1 mice following treatment with a disease
modifying therapy. We therefore examined the effect of treatment
of SOD1 mice with arimoclomol, which we have previously shown
to significantly delay disease progression and extend the lifespan of
SOD1 mice [29,30]. Therefore, in this study a separate group of
SOD1 mice were treated with arimoclomol (10 mg/Kg; i.p;
SOD1+A) from 35 days and their plasma was collected at 65, 90,
105 and 120 days of age for analysis of NfH levels.
As can be seen in Fig. 6A, even at 65 days, a pre-symptomatic age,
the effects of arimoclomol were reflected in a reduction in the plasma
mean levels of NfHSMI34 in treated SOD1+A mice compared with
vehicle treated SOD1 littermates. Thus, at 65 days, the mean 6
S.E.M of plasma NfHSMI34 levels were 17.868.8 ng/mL in
SOD1+A mice compared with 46.2613.1 ng.mL in SOD1 mice
(Mann-Whitney test, p = 0.035). As disease progressed, plasma
NfHSMI34 levels continued to be lower in arimoclomol treated than
vehicle treated SOD1 mice. Thus, the mean 6 S.E.M NfHSMI34
levels in SOD1+A mice compared with SOD1 mice were
66.3623.7: 81.8615.8 (SOD1+A: SOD1) ng/mL at 90 days;
124.8618.8: 155.4619.3 ng/mL at 105 days and 231.7623.9:
328.4640.3 ng/mL at 120 days. However, the reduction in
NfHSMI34 level in symptomatic SOD1+A mice compared with
SOD1 mice only reached significance at 120 days (90 days
p = 0.154,Mann-Whitney test; 105 days, p = 0.264, t-test; 120 days,
p = 0.048, t-test; Fig. 6).
Similarly, plasma levels of NfHSMI35 were lower in SOD1+A
mice compared with SOD1 mice at all stages of the disease
(Fig. 6B). In contrast to NfHSMI34 levels, the assay for variably-
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phosphorylated NfH did not detect any significant effects of
arimoclomol at pre-symptomatic stages. However, levels of
NfHSMI35 in SOD1+A mice at 65 days of age were more
consistent between different animals and at a lower level than
observed in SOD1 mice, where there was a greater variation in
plasma NfHSMI35 levels. Thus, the mean6S.E.M levels of plasma
NfHSMI35 in SOD1+A and SOD1 mice (SODA: SOD) were
35.1610.3: 74.0620.8 ng/mL at 65 days; 55.4615.5:
68.8614.8 ng/mL at 90 days; 77.0610.1: 104.8617.0 ng/mL
at 105 days and 92.0615.5: 161.0621.5 ng/mL at 120 days
(Mann-Whitney test, p-values: 0.391; 0.327; ,0.001 and 0.009 at
65, 90, 105 and 120 days, respectively; Mann-Whitney test).
Furthermore, a comparison of the relative plasma levels of the
two NfH phosphoforms revealed that NfHSMI34 levels were
significantly lower in SOD1+A mice than SOD1 mice at 65 days
of age (Mann-Whitney test, p = 0.015). Furthermore, in SOD1+A
mice, levels of NfHSMI34 became greater than NfHSMI35 in general
in later stages, compared with SOD1 mice, and became significant
at 105 days (p = 0.04). Thus, the disease modifying effects of
arimoclomol in SOD1 mice were reflected in lower levels of both
NfH phosphoforms as well as a more even composition of plasma
NfH phosphoforms than in vehicle treated SOD1 mice.
The Reduction in Plasma NfH Levels Reflect the
Improvement in Muscle Force, Motor Unit and Motor
Neuron Survival in Arimoclomol Treated SOD1 Mice
In order to determine if changes in plasma NfH levels could be
used to detect the beneficial effects of arimoclomol, we first
established that arimoclomol did in fact improve disease progres-
sion in SOD1+A mice, as we have previously reported [29,30].
The results are shown in Table 1, which shows the mean muscle
force, motor unit survival and motor neuron survival in SOD1+A
mice and vehicle treated SOD1 littermates, at 105 and 120 days of
age. The results confirm that there is a significant improvement in
force, functional motor unit survival and the number of motor
neurons that survive in the sciatic motor pool in SOD1+A mice
compared with their vehicle treated SOD1 littermates, at both at a
symptomatic (105d) but more clearly at a late stage (120d) of
disease. These results also show that arimoclomol largely prevents
the decline in muscle function and motor neuron survival that
occurs in untreated SOD1 mice between 105 and 120 days of age.
Discussion
In this study, we have validated plasma NfH levels as a marker
of late stage disease progression and treatment response in an
animal model of ALS. Plasma is a readily available biological fluid
that is easy to sample in longitudinal studies of progressive
neurodegenerative disorders such as ALS. As shown in Fig 1, our
results show that plasma NfH levels increase significantly during
overall disease progression between 65–120 days in the
SOD1G93A mouse model of ALS (Friedman test: p,0.0001) and
that this increase in plasma NfH correlates with the loss of muscle
force, decline in motor unit survival and most significantly, with
the extent of motor neuron degeneration that occurs during later
stages of disease. Moreover, our results also show that plasma NfH
levels are a sensitive readout of late stage disease severity that can
reflect the effects of a disease modifying therapy. Thus, in SOD1
mice treated with arimoclomol, we not only observed a significant
delay in disease progression as previously reported [29,30],
reflected in an improvement in muscle force, motor unit and
motor neuron survival, but we also detected a reduction in plasma
NfH levels compared with vehicle treated age-matched SOD1
littermates. Arimolcomol is currently in a Phase II/III clinical trial
in ALS [31,33,34]. The findings of this study therefore may
represent an important step in the development of an easily
accessible, comprehensive marker for ALS that may have utility in
future clinical trials, particularly since patients are usually
diagnosed and recruited into trials well after the onset of
symptoms.
Although previous reports have suggested that NfH levels may
be a candidate biomarker for ALS and other progressive
neurodegenerative diseases including AD and PD [21,22,27,35],
most of these studies have examined CSF as the target biological
fluid. This approach necessitates the use of a relatively invasive
procedure i.e. lumbar puncture, which is not suitable for repeated
sampling in longitudinal assessment of disease progression in
individuals suffering from ALS. Analysis of plasma NfH is the
obvious solution to this problem, but this can be technically
challenging due to the so-called ‘‘hook effect’’. This is caused by
the tendency of neurofilaments to aggregate, resulting in masking
of its epitopes and consequently, lower and un-representative
yields in commonly used ELISA techniques [28]. The ‘‘hook
effect’’ has to date, therefore prevented the reliable measurement
of neurofilament levels in ALS and other diseases where NfH
aggregate formation occurs by standard immunoassay. In this
respect, the methodology used in this study to determine plasma
NfH levels is unique, in so far it is the first specifically devised to
overcome the ‘hook effect’ and, unlike previous methods, is
sensitive enough to even detect NfH in plasma of WT mice [28].
Although the anatomically defined blood-brain barrier (BBB)
and the functionally defined blood-CSF barrier (BCB) limit CNS-
to-blood transfer, molecules expressed in the CNS can still enter
the blood under both normal and pathological conditions. There is
growing evidence for impaired BBB/BCB integrity in both SOD1
mice and post-mortem spinal cord tissue of ALS patients [36]. It is
therefore not surprising that neurofilaments leak into the
circulation in both SOD1 mice and ALS patients. The method
we have recently developed [28] and used in this study was
sensitive enough to detect both hyperphosphorylated (NfHSMI34)
and variably-phosphorylated (NfHSMI35) forms of NfH in plasma
of WT animals at all ages studied. Although the two forms of NfH
were present in approximately equal amounts, the detection of
hyperphosphorylated NfH in the plasma of healthy WT mice
shows that the presence of hyperphosphorylated NfH in the
peripheral blood is not in itself indicative of pathology. Moreover,
since NfH has been detected in several pathological conditions [9],
its presence is not disease specific and it cannot therefore be used as a primary
diagnostic biomarker for neurodegenerative conditions such as ALS. However,
plasma NfH levels do not reflect the earlier stages of disease in
SOD1 mice, although we did observe a far larger variation in
Figure 3. The correlation between plasma NfH phosphoform levels and hindlimb muscle force in SOD1 mice during disease
progression. (A) Examples of recordings of maximum tetanic (arrow) and twitch (arrow head) tension in TA muscles of WT and vehicle treated SOD1
mice at 105 days of age. (B) The bar chart shows the mean maximum twitch tension (g) of TA (filled bars) and EDL (open bars) muscles. (C) The bar
chart shows the mean maximum tetanic tension (g) of TA (filled bars) and EDL (open bars) muscles. (D)The graph shows the percentage loss of TA
maximum tetanic tension, relative to WT, and the corresponding plasma NfHSMI34 (black squares) and NfHSMI35 (black triangles) levels in vehicle
treated SOD1 mice at each stage of disease (indicated by arrows). Exponential regression lines are shown for NfHSMI34 (thick black line) and NfHSMI35
(thin black line). Error bars = S.E.M. Mann-Whitney Test: *p,0.05; **p,0.01; ***p,0.0001.
doi:10.1371/journal.pone.0040998.g003
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Figure 4. The correlation between plasma NfH phosphoform levels and motor unit survival in EDL muscles in SOD1 mice during
disease progression. (A) Typical examples of motor unit traces in the EDL muscle of a WT and a vehicle treated SOD1 mouse at 105 days of age.
(B) The bar chart shows the mean motor unit survival (numbers) in EDL muscles of WT (open bars) and vehicle treated SOD1 (filled bars) mice. (C) The
percentage loss of EDL motor units, relative to WT, and plasma NfHSMI34 (black squares) and NfHSMI35 (black triangles) levels in SOD1 mice at each
stage of disease (indicated by arrows). Exponential regression lines are shown for NfHSMI34 (thick black line) and NfHSMI35 (thin black line). Error bars =
S.E.M. Mann-Whitney Test: *p,0.05; **p,0.01; ***p,0.0001.
doi:10.1371/journal.pone.0040998.g004
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Figure 5. The correlation between plasma NfH phosphoform levels and motor neuron survival in SOD1 mice during disease
progression. (A) The photomicrographs show cross-sections of the lumbar region at L5 level of spinal cords from a WT and a vehicle treated SOD1
mouse at 105 days of age stained for Nissl. The location of the sciatic motor pool is indicated within the broken circle. Magnificent: 5X. Scale
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plasma NfH levels than in WT mice, even prior to symptom onset
(65 days), when the NfH levels were not statistically different in
SOD1 and WT mice (Fig. 1). Plasma NfH levels increased
significantly in SOD1 mice between 105 to 120 days of age (Fig. 1).
The sensitivity and reliability of the method used in the present
study is highlighted by a comparison of our results with those of
previous reports investigating plasma NfH as a potential
biomarker of ALS. Thus, one study failed to detect any NfHs in
plasma from WT mice and reported NfH levels in end-stage
SOD1G93A mice on average below 75 ng/mL [37] and the other
study only detected NfH in plasma of end-stage SOD1G93A mice
at very low levels (on average, 8 ng/mL) [38]. In contrast, using
the method employed in the present study, plasma NfH levels can
be detected in WT mice at all ages studied, as well as in
presymptomatic and end-stage SOD1G93A mice, in which mean
NfH levels rise to as high as 318.11 ng/mL [28].
In addition to examining changes in plasma NfH levels in
SOD1G93A mice, we also compared the relative levels of the two
different NfH phosphoforms, NfHSMI35 and NfHSMI34. Our
results show that at 65 days of age, in both WT and SOD1 mice,
the plasma levels of NfHSMI35 and NfHSMI34 were similar to each
other. However, by 90 days, a clear change in the relative levels of
the two NfH phosphoforms was detected, with an increase in
NfHSMI34 levels and a decline in NfHSMI35. It is possible that this
change in the relative level of hyperphosphorylated NfH is a better
indicator of pathology than simply the presence of this phospho-
form per se. Thus, our results i) demonstrate the early involvement
of NfH in pathology in SOD1 mice, ii) reveal the true abundance
of NfH in the plasma of these mice and iii) suggest that an increase
in the ratio of hyperphosphorylated NfH: variably phosphorylated
NfH is indicative of pathology, at least in the SOD1G93A mouse
model of ALS.
In order to examine whether the increase in plasma NfH was a
good reflection of the decline in neuromuscular function that
occurs during disease progression in SOD1 mice, we performed a
correlation analysis of plasma NfH levels with longitudinal and
acute outcome measures. We found a strong-moderate inverse
correlation between plasma NfH levels (both NfHSMI34 and
NfHSMI35) and grip strength in SOD1 mice between 65–120 days
of age. Grip strength is a general functional test widely used to
evaluate motor function in mouse models [39–41]. However, grip
strength is an overall measure of neuromuscular function that
predominantly reflects the function of forelimb muscles, which are
affected relatively late in disease progression in SOD1 mice. We
therefore also correlated NfH levels with quantitative, reproduc-
ible physiological assessments of neuromuscular function in
hindlimbs. We observed a moderate-strong correlation in the
decline in muscle force (Fig. 3D) and increased plasma NfH and a
mild correlation between plasma NfH and EDL motor unit loss
(Fig. 4C) in SOD1 mice. The mild correlation between NfH levels
and motor unit survival is likely to be a reflection of the relatively
late involvement of the EDL muscle in disease in SOD1 mice
[30,32], so that motor unit loss in other muscles such as TA which
is affected earlier and to a greater extent than EDL, may correlate
better with NfH levels than EDL, but are technically more difficult
to accurately estimate. Thus, the extent of motor unit loss in any
individual muscle may not be a good measure of overall disease
progression. Among the most direct measures of disease progres-
sion in ALS is the extent of motor neuron survival. It has long been
thought that the loss of motor neurons in ALS is linear [42] and in
the present study, morphological assessment of motor neuron
survival at different ages reveals that motor neuron survival
declines linearly in SOD1 mice. More importantly, we found a
strong correlation between the extent of motor neuron degener-
ation and plasma NfH levels in SOD1 mice (Fig. 5C). These
results show that plasma NfH levels, at least detected by the
method described in this study, can be used to reflect the extent of
motor neuron degeneration. Thus, our data clearly shows that
longitudinal measurement of plasma NfH levels in SOD1 mice
reveals that plasma NfH levels increase as disease progresses,
particularly in later stages between 105–120 days which is also the
most critical period of disease progress in transgenic SOD1G93A
bar = 250 mm. (B) The bar chart shows the mean motor neuron survival in SOD1 mice expressed as a percentage of that in age-matched WT
littermates at various stages of disease. (C) The percentage motor neuron death in SOD1 mice and levels of plasma NfHSMI34 (black squares) and
NfHSMI35 (black triangles) at each disease stage (indicated by arrows). Exponential regression lines are shown for NfHSMI34 (thick black line) and
NfHSMI35 (thin black line). Error bars = S.E.M. Mann-Whitney Test: *p,0.05; **p,0.01; ***p,0.0001.
doi:10.1371/journal.pone.0040998.g005
Figure 6. Longitudinal assessment of plasma NfH levels in
arimoclomol treated SOD1 mice. The graphs show the mean
plasma level (ng/ml) of A) NfHSMI34 and B) NfHSMI35 in vehicle treated
SOD1 mice (circles; n = 19) and arimoclomol treated SOD1+A mice
(triangles; n = 19), at 65 (pre-symptomatic), 90 (early symptomatic), 105
(late symptomatic), and 120 (end stage) days of age. Error bars = S.E.M.
A t-test was performed for direct comparison of the levels of NfHSMI34 in
the two groups at 105 and 120 days, and a Mann-Whitney Test was
performed for the other time points as the data was not normally
distributed. Non-parametric analyses take the median value into
account more than the mean value in the statistical analysis. *p,0.05;
**p,0.01.
doi:10.1371/journal.pone.0040998.g006
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mice model, and this increase in NfH levels correlate with the
decline in muscle force and the death of motor neurons.
However, it should be noted that, there is likely to be a
significant delay between the time that the first physical
manifestations of disease occur (such as muscle denervation
[43]), and when these result in functional deficits (such as reduced
muscle force), and the appearance of Nfs in the peripheral blood.
Thus, when the timeline between muscle denervation, axonal
degeneration, formation of NfH-containing aggregates, MN death
and the eventual entry of NfH into peripheral blood is taken into
account, it is not surprising that there is a discrepancy in the time
between the detection of early physical manifestations of the
disease (90 days) and the first significant elevation in plasma NfH
levels (105 days). However, the invasive physiological and
morphological approaches used to determine the extent of disease
in SOD1 mice in this study, although very sensitive, quantitative
and accurate, are irreversible and not practical for longitudinal
follow-up in mice. Moreover, these measures might not be
clinically relevant for human as they may not reflect the state of
disease in patients when they first present to their physician with
symptoms. Therefore, the correlations we report between the
increases in plasma NfH levels and the decline in neuromuscular
function may provide a safe and easy measure for the evaluation of
later disease progression in ALS.
Furthermore, our results also show that plasma NfH levels
reflect the disease modifying effects of arimoclomol in SOD1 mice.
In confirmation of our previous findings [29,30], we found that
treatment with arimoclomol significantly delays the decline in
neuromuscular function and death of motor neurons in SOD1
mice (Table 1). Furthermore, plasma NfH levels were in general
lower in arimoclomol treated SOD1+A mice than vehicle treated
SOD1 littermates at all ages studied, but most significantly at later
stages of disease, from 105–120 days of age (Fig. 6). Hence, at
65 days, a pre-symptomatic age, plasma levels of NfHSMI34 were
significantly lower in arimoclomol-treated SOD1+A mice com-
pared with vehicle treated SOD1 littermates, possibly due to the
early beneficial effects of arimoclomol in the periphery, at the
neuromuscular junction (NMJ). Arimoclomol acts as a co-inducer
of the heat shock response, so that it only acts in cells under
conditions of cellular stress to augment the heat shock response
(HSR; [44]). Thus, although the neuroprotective effects of
arimoclomol in SOD1 mice only manifest later in the disease
when motor neurons are under considerable stress [29,30]), our
recent results indicate that its beneficial effects in the periphery
manifest earlier in the disease, prior to symptom onset. It has now
been established that the earliest physical manifestation of disease
in SOD1 mice occurs at the NMJ, where significant muscle
denervation occurs prior to any motor neuron death [43]. Our
recent work has shown that this early denervation is accompanied
by an increase in the HSR and correspondingly, in arimoclomol
treated SOD1 mice, this stress response is augmented, resulting in
a delay in muscle denervation [45]. Therefore, since the levels of
NfH remain steady in WT mice throughout the study, the
difference in plasma NfH levels observed in SOD1+A and SOD1
mice at 65 days of age is likely to be the result of Arimoclomol’s
early beneficial effects in the periphery and the maintenance of
neuromuscular contacts.
However, as shown in Fig. 6 and Table 1, the significant
improvement in muscle force, motor unit and motor neuron
survival observed from 105 days of age in arimoclomol treated
SOD1+A mice compared with their vehicle treated SOD1
littermates is reflected in a decrease in plasma NfH levels.
Although the significance of reduction of NfHSMI35 observed from
105 days was in line with the physiological improvement, the
reduction of NfHSMI34 became significantly reduced only at
120 days of age. However, further analysis of the levels of the two
NfH phosphoforms showed that the relative increase in the more
pathological plasma NfHSMI34 compared with NfHSMI35 occurred
significantly later in SOD1+A mice than SOD1 mice (data not
shown). It is likely that the difference in the timing of the effects of
arimoclomol treatment on NfHSMI35 and NfHSMI34 levels may be
related to their different levels of phosphorylation. Since the
stability of NfH increases with the degree of phosphorylation [10],
it will take longer for proteases to cleave hyperphosphorylated
NfH compared with variable-phosphorylated NfH. Because
neurofilament aggregates containing a large quantity of hyperpho-
sphorylated NfH are a hallmark of disease in SOD1 mice, it will
take longer for hyperphosphorylated NfH levels to decrease
following treatment with arimoclomol compared with variable-
phosphorylated NfH.
Taken together our results show that the late stage decline in
neuromuscular function and motor neuron survival in SOD1 mice
is correlated with an increase in plasma NfH phosphoform levels,
and furthermore, that plasma NfH phosphoform levels reflect the
improvement in disease phenotype induced by treatment with
arimoclomol. Plasma NfH phosphoform levels may therefore be a
useful marker to determine late stage disease progression in ALS
and that may eventually be used as a sensitive outcome measure in
clinical trials, particularly since ALS patients are likely to exhibit
significant disease symptoms by the time of enrolment. The
current outcome measures used in clinical trials are not
particularly sensitive to change over disease progression and
usually require a long period of observation, typically longer than
1 year. Even measurements that are capable of detecting the rapid
degeneration of motor neurons in ALS, such as MUNE [46], have
drawbacks, such as the need for specialist training, equipment and
complex statistical analysis, together with the lack of a gold
standard method, which prevents the widespread use of MUNE as
an outcome measure in ALS [47]. Moreover, as the results of this
study show, the selection of specific individual muscles for MUNE
may not always give an accurate reflection of the extent of disease
progression in other muscle groups variably affected by disease.
Accurate and sensitive assessment of plasma NfH phosphoform
levels may therefore provide a quick and easy readout of disease
Table 1. Arimoclomol delays disease progression in SOD1 mice.
Age (days) Group
Maximum TA Tetanic Force
(g ± sem) (n = muscle examined)
EDL MU survival (n ± sem)
(n = muscle examined)
MN survival (%WT) (n = sciatic
motor pool examined)
105 SOD1 SOD1+A 21.163.0 (16) 49.269.9 (11)** 12.660.5 (15) 14.860.5 (12)** 44.8 (10) 58.0 (10)**
120 SOD1 SOD1+A 19.563.5 (12) 36.969.0 (10)** 10.760.7 (11) 14.060.6 (10)** 29 (10) 65 (10)**
The Table shows the maximum TA tetanic force, EDL Motor Unit survival and Motor Neuron Survival in vehicle treated SOD1 and arimoclomol treated SOD1+A mice at
105 and 120 days of age. The results are the mean 6 sem. **p,0.01.
doi:10.1371/journal.pone.0040998.t001
Plasma Neurofilaments as Late Stage Markers in ALS
PLoS ONE | www.plosone.org 10 July 2012 | Volume 7 | Issue 7 | e40998
progression in individual patient in future clinical trials. In
addition, plasma NfH levels may also serve as a safety biomarker
as a rapid increase in plasma NfH phosphoform levels following
administration of test drugs might indicate a detrimental treatment
effect [48]. The use of plasma NfH as an outcome measure may
therefore help to improve the safety of clinical trials by speeding up
the time taken to detect deleterious effects and by reducing the
time taken to complete these studies, hence reducing costs of Phase
III trials which account for 70% of costs of clinical drug
development in ALS [49]. Whether our findings in an animal
model of ALS can be translated to ALS patients will become clear
through further longitudinal investigation on cohorts of ALS
patients. If the results observed in this study in an animal model of
ALS are translated into patient samples, accurately measured
plasma NfH phosphoform levels may become a valuable
biomarker of disease progression, especially in later stages, for
the ALS community.
Materials and Methods
Experimental Animals
All animals were bred and maintained by Biological Services in
the UCL Institute of Neurology. The experiments described in this
study were carried out under licence from the UK Home Office
and following approval from the UCL Institute of Neurology’s
Ethical Review Panel. Transgenic mice expressing human
SOD1G93A mutant protein (TgN[SOD1-G93A]1Gur; Jackson
Laboratories, Bar Harbour) were maintained by breeding male
heterozygous carriers with female (C57BL/66 SJL) F1 hybrids.
The presence of the SOD1G93A mutation was confirmed by PCR
reaction from ear biopsies in all mice at the age of 3 weeks. In
order to obtain maximum blood sample volume of mice between
65–120 days of age whilst still complying UK Home Office
Regulations (Less than 15% of the blood volume should be
removed in any 30-day period, i.e. 10.5 ml/kg) [50], only male
mice were examined in this project.
Experimental Groups. Depending on Genotype, the Mice
were Randomly Assigned to One of 3 Groups
1) Transgenic mice carrying human SOD1G93A mutant
protein treated daily with arimoclomol (10 mg/Kg; i.p)
from 35 days of age (SOD1+A mice).
2) Transgenic mice carrying human SOD1G93A mutant
protein treated daily with vehicle (sterile saline; i.p) from
35 days of age (SOD1 mice).
3) Untreated wild type, age-matched littermates (WT mice).
4) Arimoclomol (kind gift of Biorex R&D Co., Hungary) was
dissolved in sterile saline (2 mg/ml) and the solution stored
at 4uC for a maximum of 1 week.
Longitudinal biomarker study. In the longitudinal study of
plasma NfH levels, arimoclomol treated SOD1 mice (SOD1+A;
n= 19), vehicle treated SOD1 mice (SOD1; n= 19) and untreated
wild-type (WT; n= 13) mice were repeatedly examined at various
stages of disease progression ranging from early symptomatic to
end-stage disease.
Plasma collection. Blood sampling was carried out in mice
from each experimental group at 65, 90, 105 and120 days of age,
representing pre-symptomatic, early-symptomatic, late-symptom-
atic and late stage disease. At 65, 90 and 105 days, the mice were
placed in a recovery chamber (Peco Service; V1200), set at
38.5uC, for 15 minutes and then transferred into a plastic tube
with the tail exposed. Blood was collected from the tail vein into an
EDTA-coated tube (BD MicrotainerH, K2E). At 120 days, blood
was collected by a cardiac puncture, under terminal anaesthesia
using pentobarbital. Each tube was then centrifuged at
14,000 rpm for 8 min. The plasma was collected and protease
inhibitor added (Sigma; v/v: 1/100). Each sample was then
aliquoted and stored at 280uC until further analysis. In total,
plasma samples collected from 19 SOD1 mice, 19 SOD1+A mice,
and 13 WT mice at each time point were used for further analysis
in this study.
Functional Assessments
Grip strength. In the same mice selected for plasma
collection, grip strength was determined prior to blood collection.
According to the manufacturer’s instruction (Bioseb, BIO-GS3),
mice were placed on a horizontal grid and pulled by the tail
against the direction of the force gauge until the animal released
the grid. An average of four readings was obtained at each
occasion.
Acute in vivo physiological assessment of neuromuscular
function and motor unit survival. In a separate set of mice,
functional analysis of hindlimb muscle function was undertaken at
105 days of age, corresponding to a late symptomatic stage of
disease. WT (muscle n= 10), SOD1 (muscle n= 12) and SOD1+A
(muscle n= 16) mice were deeply anesthetised (4.5% chloral
hydrate; 1 ml/100 g of body weight, i.p.) and prepared for in vivo
analysis of isometric muscle force (as described in Kalmar et al.,
2008 [30]). The distal tendons of the Tibialis Anterior (TA) and
Extensor Digitorum Longus (EDL) muscles in both hindlimbs
were dissected free and attached by silk thread to isometric force
transducers (Dynamometer UFI Devices, Welwyn Garden City,
UK). The sciatic nerve was exposed and sectioned. The length of
the muscles was adjusted for maximum twitch tension. The
muscles and nerve were kept moist with saline throughout the
recordings and all experiments were carried out at room
temperature. Isometric contractions were elicited by stimulating
the nerve to TA and EDL using square-wave pulses of 0.02 ms
duration at supra-maximal intensity, via silver wire electrodes.
Contractions were elicited by trains of stimuli at frequencies of 40,
80 and 100 Hz. The maximum tetanic tension was measured
using a computer and appropriate software (PicoScope).
The number of motor units innervating the EDL muscles was
also determined by stimulating the motor nerve with stimuli of
increasing intensity, resulting in stepwise increments in twitch
tension due to successive recruitment of motor axons with
increasing stimulus thresholds. The number of stepwise increments
was counted to give an estimate of the number of functional motor
units (MUNE) present in each muscle.
Morphological assessment of motor neuron
survival. Following physiological assessment of muscle function,
the mice (n = 5 per group) were terminally anaesthetised and
perfused transcardially with saline followed by fixative containing
4% paraformaldehyde (PFA). The spinal cords were then removed
and postfixed in 4% PFA and cryopreserved in 30% sucrose
overnight at 4uC. Transverse sections (20 mm) of the fixed lumbar
spinal cords (L3–L6) were cut on a freezing cryostat and collected
serially onto glass slides and subsequently stained for Nissl
(gallocyanin). Large polygonal neurons, with a minimum diameter
of 20 mm, within the sciatic motor pool, which had a clear
nucleolus and a distinct Nissl-dense cytoplasm were counted in
every 3rd section, in order to prevent counting the same neuron
twice in consecutive sections [51].
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NfH ELISA
We have recently developed a sensitive, reproducible method
for the detection of NfHs in plasma, which breaks-up NfH
aggregates, thereby allowing reliable quantification of plasma NfH
levels using ELISA [28]. In this ELISA, NfH levels in plasma from
mice in each experimental group were determined using mouse
monoclonal anti-NfH antibodies, SMI-34R and SMI-35R (Cov-
ance, USA) as the capture antibodies, rabbit polyclonal anti-
Neurofilament 200 (N4142; Sigma, UK) as the detector antibody,
and horseradish peroxidase (HRP)-labelled swine polyclonal anti-
rabbit antibody (P0217; DAKO, Denmark) as the reporter
antibody. NfH detected with the SMI-34R capture antibody is
labelled as NfHSMI34, while NfH detected with the SMI-35R
capture antibody is labelled as NfHSMI35. For a full description of
this 4-layer sandwich ELISA and the reagents used see [28].
Analytical procedure. The microtitre plates were coated
with 100 ml of capture antibodies, either SMI-34R or SMI-35R, in
0.05 M carbonate buffer, pH 9.5 (w/v, 2/10000), at 4uC
overnight. The plates were rinsed once in Barb2EDTA buffer
(13.1 g Sodium Barbitone, 2.1 g Barbital, 0.25 g EDTA) contain-
ing 0.05% Tween 20 and 0.1% BSA (wash solution) and then
blocked with 150 ml of Barb2EDTA buffer containing 1% BSA at
room temperature (RT) for 1 hour. Meanwhile, 5 mL of original
plasma was added to 35 mL of Barb2EDTA buffer containing
0.5 M urea and mixed well at RT for 1 hour. After 2 rinses with
wash solution, 95 ml of Barb2EDTA buffer containing 0.1% BSA
(sample diluent) was added into each well. Five microliters of
standard was added to standard wells, and sample wells were
loaded with 5 mL of the diluted urea-treated plasma. Quality
controls were also included, which consisted of pre-prepared NfH
samples of various concentrations. All samples, standards and
quality controls were loaded in duplicate. Plates were then
incubated for 1 hour (RT) on a shaker. After washing (365 mins),
100 ml of detector antibody (w/v. 10/10000 in sample diluent) was
added into each well and incubated for 1 hour on a shaker (RT).
Plates were then washed (365 mins) before 100 ml of reporter
antibody (w/v, 10/10000 in sample diluent) was loaded into each
well and incubated for 1 hour on a shaker (RT). After washing
(665 mins), 100 ml of TMB substrate was added into each well
and incubated for approximately 20 minutes in the dark on a
shaker (RT). The reaction was then stopped by adding 50 ml of
1 M HCl into each well. The absorbance was read immediately at
450 nm, with 750 nm as the reference wavelength, on an Omega
plate reader (Software version: 1.02; BMG LABTECH).
Data analysis. Measurements with a coefficient of variation
(CV) value higher than the assay limit (10%; [52]) were repeated.
Quality control samples were used throughout and absorbance
readouts from different microtitre plates were adjusted to the
quality control readout to allow comparison of results across
different plates.
Statistical Analysis
Statistical analysis was carried out using SPSS software (V17).
The normality of data was checked, using a Kolmogorov-Smirnov
test, to determine the approach of parametric or nonparametric
analysis. The repeated Friedman test was used for analysis of NfH
levels within groups in the longitudinal biomarker study. The
Mann-Whitney test or t-test, according to the normality of data,
was used for analysis of NfH levels between groups at each time
point (WT v.s. SOD1; SOD1 v.s. SOD1+A), and for analysis of
the levels of the two NfH phosphoforms in each group, at different
time points (NfHSMI34 v.s. NfHSMI35). Bivariate correlation
analysis, using Spearman’s correlation coefficient, was examined
for plasma NfH levels and grip strength. A minor, moderate and
strong correlation is considered if Spearman’s rho (R) is,0.3, 0.3–
0.5,.0.5, respectively. Statistical significance was set at p,0.05.
Exponential analysis was used to determine the correlation of
plasma NfH levels and functional readouts in SOD1 mice at
various disease stages. A strong correlation was considered when
the coefficient of determination (R2) obtained from the exponential
analysis was greater than 0.8.
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